News Sentiment

EVO sentiment intelligence

Evotec SE ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 2.79 Week of 10 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

74/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-4.0% over one week, +2.4% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

Berenberg cuts Evotec stock rating on guidance downgrade

Market Reaction

Price moving ahead of tone

58/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 74/100 classification
One-week reaction -4.0% Price reacting lower
Trend fit Trend inactive 2.4% over four weeks
Fair value -46.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 22
Negative 14

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Investing.com 9
TradingView 7
Stock Titan 6
AD HOC NEWS 6
MT Newswires 3
Investing.com Canada 2
ad-hoc-news.de 2
Ad Hoc News 2

Event Lens

What the news is about

Classified themes
Market update 20
Earnings 18
Analyst action 7
Guidance 3
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-49 of 49
AD HOC NEWS Direct company coverage

Evotec SE develops partnerships in drug discovery. The biotech group expands its global footprint

Evotec SE is expanding its global footprint by building long-term partnerships with pharmaceutical companies and research institutions to translate early-stage science into commercial therapies. The German biotechnology company focuses on integrated research and development, util

Tone
Positive 92/100
Event
Market update
Published
07 Jul 2026 12:13
Source
AD HOC NEWS
TradingView Direct company coverage

Price to sales forward of Evotec SE – SIX:EVT

This article displays the "Price to sales forward" metric for Evotec SE (SIX:EVT). It is part of the financial data provided by TradingView, sourcing market data from ICE Data Services and reference data from FactSet. The page is an embedded financial data display rather than a t

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 06:13
Source
TradingView
AD HOC NEWS Direct company coverage

Evotec SE refines its drug discovery model as global biotech demand stays robust

Evotec SE is refining its drug discovery and development platform to capitalize on robust global biotech demand and outsourcing trends. The company operates a hybrid business model combining fee-for-service revenue with milestone and royalty participation from partnered projects,

Tone
Neutral 50/100
Event
Earnings
Published
06 Jul 2026 13:20
Source
AD HOC NEWS
AD HOC NEWS Direct company coverage

Evotec SE outlines its science-driven growth path as investors track long-term partnerships

Evotec SE is a German biotechnology company that partners with pharmaceutical and biotech organizations to discover and develop new medicines. The company leverages its scalable discovery and development platforms, combining fee-for-service revenues with co-owned projects that of

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 18:40
Source
AD HOC NEWS
AD HOC NEWS Direct company coverage

Evotec SE outlines long-term growth ambitions as drug discovery demand evolves

Evotec SE is positioning itself as a key partner in drug discovery and development, focusing on integrated solutions and a partnership model with pharmaceutical and biotech clients. The company aims for long-term growth by expanding its technological capabilities, diversifying th

Tone
Positive 76/100
Event
Deals and strategy
Published
05 Jul 2026 10:23
Source
AD HOC NEWS
TradingView Direct company coverage

EVTA Forecast — Price Target — Prediction for 2027

The article provides a price target for Evotec SE Sponsored ADR (EVTA) based on analyst forecasts. Nine analysts have offered 1-year price forecasts, although specific maximum and minimum estimates are not provided. The content also briefly touches on common financial metrics lik

Tone
Neutral 50/100
Event
Analyst action
Published
05 Jul 2026 03:10
Source
TradingView